News
Monday, the FDA approved Merck & Co Inc’s (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 4:15 pm ...
US FDA Approves Merck's RSV Antibody ... The CDC currently recommends two immunization options for babies to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or ...
CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment is called Enflonsia. It is a monoclonal antibody made by Merck.
Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus. Skip to content. Main Navigation. Search. Search for: Local Weather ...
The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results